NCT05439005

Brief Summary

This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
158

participants targeted

Target at below P25 for phase_3 breast-cancer

Timeline
13mo left

Started Dec 2022

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Dec 2022Jun 2027

First Submitted

Initial submission to the registry

June 27, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 30, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

December 7, 2022

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2027

Last Updated

January 30, 2026

Status Verified

January 1, 2026

Enrollment Period

4.5 years

First QC Date

June 27, 2022

Last Update Submit

January 28, 2026

Conditions

Keywords

free flap reconstruction surgeryanaesthesia

Outcome Measures

Primary Outcomes (1)

  • comparison of Morphine consumption in the two groups

    during the first 48 hours postoperatively

Secondary Outcomes (13)

  • Assessment of vasopressor requirement and total intraoperative filling volume

    end of surgery

  • Assessment of the state of consciousness on arrival in the PACU

    on arrival in the PACU

  • Assessment of the incidence of PONV in the PACU, at D0, D1 and D2

    in the PACU, at D0, D1 and D2

  • Maximum VAS at rest and mobilization in the PACU, at D0, D1 and D2

    in the PACU, at D0, D1 and D2

  • Dose of morphine given in titration in the PACU (mg)

    in the PACU

  • +8 more secondary outcomes

Study Arms (2)

OFA group

EXPERIMENTAL

OFA (Opioid Free Anaesthesia) group:

Drug: Dexmedetomidine

CA control group

NO INTERVENTION

CA (Conventional Anaesthesia) control group:

Interventions

Dexmedetomidine+Lidocaine

OFA group

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPatient eligible for free flap reconstruction surgery of the breastunder general anaesthesia.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women aged 18 or older.
  • Patients with a French health insurance coverage (having a French social security number).
  • Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia.
  • Patient who has given written consent to participate in accordance with the regulations.
  • Having a negative blood pregnancy test for patients of childbea ring age.

You may not qualify if:

  • Allergy or intolerance to any of the drugs (dexmedetomidine, remifentanil, lidocaine, propofol, dexamethasone, kétamine, ketoprofen, nefopam, paracetamol, morphine, ropivacaine, droperidol, ondansetron).
  • Known history of heart failure, arrhythmias and/or ischemic heart disease and/or severe renal insufficiency.
  • Pulse below 50bpm during anaesthesia consultation and/or under beta blocker treatment.
  • Treatment with ACEI/ARB.
  • Severe asthma.
  • Symptomatic gastric or duodenal ulcer with or without treatment.
  • Baseline systolic blood pressure \< 100 mmHg.
  • Chronic preoperative pain and/or use of WHO ladder step 2 or 3 analgesics preoperatively.
  • Patient already included in another therapeutic trial evaluating an experimental molecule.
  • Persons deprived of liberty or under guardianship.
  • Patients with suspected difficulties in assessing pain on a scale.
  • Inability to undergo trial medical monitoring due to geographic, social or psychological reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Institut Curie Paris

Paris, 75005, France

RECRUITING

Institut Curie Saint-Cloud

Saint-Cloud, 92210, France

RECRUITING

Gustave Roussy, Cancer Campus, Grand Paris

Villejuif, France

RECRUITING

Related Publications (1)

  • Saad-Boutry M, Carton M, Ezzili C, Savignoni A. Opioid-free versus opioid-based anaesthesia for free-flap reconstruction surgery of the breast: protocol for a phase III, multicentre, randomised controlled study. BMJ Open. 2025 Feb 17;15(2):e070021. doi: 10.1136/bmjopen-2022-070021.

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Mary SAAD, MD

    Institut Curie Saint-Cloud

    STUDY DIRECTOR

Central Study Contacts

Anne-Claire COYNE, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2022

First Posted

June 30, 2022

Study Start

December 7, 2022

Primary Completion (Estimated)

June 6, 2027

Study Completion (Estimated)

June 6, 2027

Last Updated

January 30, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Investigators will share de-identified data sets with interested researchers, educators or clinicians. Materials generated under the project will be disseminated in accordance with Institut Curie policies.

Time Frame
Data requests can be submitted starting 9 months after article publication and will be made accessible for up to 12 months.
Access Criteria
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific reserach, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

Locations